Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, ...
Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine ...
Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has recently received clinical trial approval ...
Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery ...
DIFF Biotech’s nasal spray influenza vaccine, DIFF-flu receives China NMPA approval: Hangzhou, China Wednesday, February 11, 2026, 15:00 Hrs [IST] Zhejiang Difference Biological ...
Emergent BioSolutions Inc. EBS stock rose Friday following the FDA approval of new multipack configurations of ...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of. Mr. Sandoval’s appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved ...
The Allan Labor Government is ensuring Victorian schools are ready to support students at risk of anaphylaxis, with two new emergency treatment ...
Neffy needle-free epinephrine spray sales surge, global expansion, and CSU Phase 2b upside. See more on SPRY here.
Emergent BioSolutions received Food and Drug Administration approval for its multipack configuration of Narcan, the opioid-overdose-reversal drug.
The agency first listed BHA as “generally recognized as safe,” or GRAS, in 1958 and approved it as a food additive in 1961.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results